source
- Pierre Fabre aligns with FDA on resubmission of Ebvallo cell therapyPierre Fabre Laboratories announced that it has reached an agreement with the U.S. Food and Drug Administration on a new path for its cell therapy Ebvallo, which had been rejected twice. The FDA w…
- Lilly, Gilead lead pharma’s M&A boomDeal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.